Jesus Alonso Gandara Mireles | Pharmacology, Toxicology and Pharmaceutical Science | Young Scientist Award

Posted on by ScienceFather

Dr. Jesus Alonso Gandara Mireles | Pharmacology, Toxicology and Pharmaceutical Science | Young Scientist Award

Researcher,  National Polytechnic Institute,  Mexico.

Jesús Alonso Gándara Mireles is an exemplary candidate for the Research for Young Scientist Award, with extensive qualifications in biotechnology. He holds a Bachelor’s degree and multiple master’s degrees, culminating in a PhD focused on pharmacokinetics and pharmacogenetics in oncology. Currently completing a Postdoctoral Fellowship at the National Polytechnic Institute, Jesús conducts research aimed at optimizing chemotherapy for pediatric cancer patients. His experience includes prestigious internships at the University at Buffalo and the University of San Diego, enhancing his expertise. As a member of key professional organizations, he demonstrates a strong commitment to advancing personalized medicine and improving patient outcomes.

Publication Profile :

Scopus

Educational Background :

Jesús’s educational achievements are impressive and relevant to his research interests. He holds a Bachelor’s degree in Biotechnology with a biomedical focus, followed by a Master’s in Molecular and Cellular Biology, a Master’s in Human Genetics, and a Master’s in Clinical Pharmacokinetics. His PhD, centered on pharmacokinetics and pharmacogenetics in oncology, underscores his specialized knowledge in this vital area of research. This rigorous academic training has equipped him with the necessary skills to tackle complex scientific problems in the field of cancer treatment.

Professional Experiences :

Jesús Alonso Gándara Mireles has accumulated extensive professional experience in biotechnology and clinical research, particularly in the fields of pharmacogenetics and pharmacokinetics. Currently, he is completing a Postdoctoral Fellowship at the National Polytechnic Institute (IPN), focusing on the pharmacokinetics of oncology agents in pediatric patients. His previous internships include significant roles in Clinical Pharmacokinetics at the National Institute of Pediatrics and Pediatric Cancer Pharmacology at the University at Buffalo. He also engaged in research on Pediatric Cancer Genetics at the University of San Diego. His work aims to optimize treatment strategies and reduce chemotherapy-induced adverse effects in childhood cancer.

Research Contribution  :

Throughout his career, Jesús has gained valuable research experience through multiple internships. His exposure to pharmacokinetics and pharmacogenetics at prestigious institutions, including the University at Buffalo and the University of San Diego, highlights his capability to engage with leading experts and contribute to groundbreaking research. His current work focuses on optimizing chemotherapy for children by reducing adverse effects through personalized medicine, emphasizing his innovative approach to healthcare challenges.

Awards And Achievements :

Jesús Alonso Gándara Mireles has earned notable recogn ition throughout his academic and research career. As a member of the National System of Researchers (CONACYT) at Level 1, he has demonstrated his commitment to advancing scientific knowledge. His research contributions have been acknowledged through prestigious internships, including those at the National Institute of Pediatrics and the University at Buffalo. Additionally, Jesús is an active member of the International Society of Pediatric Oncology (SIOP) and the Latin American Society of Pharmacogenomics and Personalized Medicine (SOLFAGEM). These affiliations reflect his dedication to pediatric oncology and personalized medicine, underscoring his impactful contributions to the field.

Conclusion : 

Jesús Alonso Gándara Mireles is an outstanding candidate for the Research for Young Scientist Award. His impressive educational background, significant research experience, and active participation in professional networks make him a valuable contributor to the field of biotechnology and pediatric oncology. His work has the potential to greatly improve treatment outcomes for children with cancer, demonstrating his commitment to advancing scientific knowledge and enhancing patient care. Therefore, I strongly endorse his nomination for this esteemed award.

Publication Top Notes :

  • “Influence of Age, Gender and Body Mass Index on Intravenous Pharmacokinetics of Buprenorphine in Children Undergoing Orthopedic Surgery” (2024) – 🏥
  • “Population pharmacokinetics and pharmacodynamics of L-asparaginase and its impact on the development of pancreatitis and hypersensitivity reactions in children with leukemia under treatment” (2024) – 🧬
  • “Nutritional Status as a Risk Factor for Doxorubicin Cardiotoxicity in Mexican Children with Acute Lymphoblastic Leukemia” (2024) – 🍽️
  • “Impact of single-nucleotide variants and nutritional status on population pharmacokinetics of Doxorubicin, and its effect on cardiotoxicity in children with leukemia” (2023) – ⚗️ Cited by: 3
  • “Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia” (2021) – 🧬 Cited by: 8
  • “Genotype Analysis of ABCC1, NCF4 and CBR3 Polymorphism and the Association With Childhood Acute Lymphoblastic Leukemia in Mexican Childhood Population” (2021) – 🔬 Cited by: 3

Shubham Sharma | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Shubham Sharma | Pharmacology | Best Researcher Award

Dr Shubham Sharma, Pfizer, United States

Dr. Shubham Sharma is a leading computational modeler with 8+ years of expertise in theoretical materials science, physics, and chemistry. Holding a Ph.D. in Chemical & Environmental Engineering from Brown University (2021), he specializes in atomistic modeling and solid-form design, notably working at Pfizer where he leads drug de-risking efforts. His research in catalysis, electrochemistry, and crystal structure predictions has earned him over 10 Pfizer Bravo awards. Dr. Sharma’s groundbreaking work is recognized globally, including invited talks at major conferences, advancing both pharmaceutical and renewable energy applications. 💻🔬💊⚡

Publication Profile

Google Scholar

Education

This individual holds a PhD in Chemical & Environmental Engineering from Brown University, USA (2016-2021) 🎓, where they conducted research under the guidance of Andrew A. Peterson 🧑‍🔬. Their academic journey began with a Bachelor of Technology (B. Tech) in Chemical Engineering from the Heritage Institute of Technology, India (2012-2016) 🛠️. With a strong foundation in chemical engineering, they have pursued advanced studies focusing on environmental solutions and sustainability 🌍. Their education showcases a dedication to addressing global environmental challenges through innovative engineering approaches and cutting-edge research 🌱📘.

Work Experience

Currently serving as a Senior Scientist in Computational Materials Science at Pfizer Inc. (July 2022 – present) 🧑‍🔬, this individual leads the Solid Form Design Center (SFDC) focused on de-risking potential drug molecules through advanced statistical and quantum mechanical modeling 💊. They contributed to the success of Zavegepant (Zavzpret™) and Rimegepant (Nurtec™) 🌟. As a core member of the Crystal Structure Prediction team, they specialize in electronic structure theory, density functional theory, and atomistic modeling 🧬. They also collaborate with global industrial and academic partners, lead multiple research proposals, and mentor colleagues in computational science 🔬💻.

Selected conference presentations

Sharma has delivered numerous invited talks and presentations globally 🌍. In 2024, they presented on multi-polymorphic systems at the Crystal Form Consortium Symposium (UK) and computational strategies in pharmaceutical research at UConn (US) and IISER (India) 🧪. Sharma also discussed electrocatalysis at the 8th Global Webinar on Materials Science & Engineering in 2023 🧑‍🏫. Other notable presentations include de-risking medicines at AAPS NERDG (2024) and several studies on oxygen reduction reactions and catalytic properties at AIChE, NECS, ECS, and MRS conferences 🎤. Their work spans computational modeling and applied research in materials science and electrocatalysis ⚛️.

Research Focus

The research focus of Sharma spans electrochemistry, catalysis, and materials science. Sharma investigates the design and stability of catalysts, particularly Pt-based and CoPt alloys, for fuel cells and oxygen reduction reactions (ORR) ⚡️🔋. His work includes dynamic stability, reaction barriers, and potential-controlled reactions, using advanced techniques like density functional theory (DFT) and experimental-theoretical integration. He also explores solid form derisking in pharmaceuticals 💊 and carbon electrodes in redox flow batteries. Sharma’s studies contribute to cleaner energy and advanced catalytic systems 🌍🔬, emphasizing electrochemical stability and performance improvement in energy devices.

 

Publication Top Notes

Hard-magnet L10-CoPt nanoparticles advance fuel cell catalysis

Anisotropic Strain Tuning of L10 Ternary Nanoparticles for Oxygen Reduction

Face-centered tetragonal (FCT) Fe and Co alloys of Pt as catalysts for the oxygen reduction reaction (ORR): A DFT study

Ordered CoPt oxygen reduction catalyst with high performance and durability

Metal dissolution from first principles: Potential-dependent kinetics and charge transfer

Assessment of carbon monoxide exposure in roadside food-vending shanties using coal cookstoves in Kolkata, India

Dynamic stability of Pt-based alloys for fuel-cell catalysts calculated from atomistics

Conclusion

Dr. Shubham Sharma’s innovative research in computational modeling and materials science, alongside his leadership in both academic and industrial collaborations, makes him an exceptional candidate for the Best Researcher Award. His contributions have not only advanced pharmaceutical drug design but also impacted renewable energy research, marking him as a distinguished leader in his field.

Hua Jin | Pharmacology | Women Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Hua Jin | Pharmacology | Women Researcher Award

Assoc Prof Dr. Hua Jin, Guangdong Medical University, China

Assoc. Prof. Dr. Hua Jin is an Associate Professor at Guangdong Medical University, Dongguan, China, specializing in nanochemistry, bionanomaterials, and drug delivery systems. He holds a PhD from Jinan University, China, and completed postdoctoral fellowships at Northwestern University and the University of Illinois at Chicago. Dr. Jin has published over 50 SCI papers with an H-index of 34, and holds multiple international and Chinese patents. His research primarily focuses on nanoparticle-based therapies for lung injuries and cancer. Notable publications include works in J Tissue Eng and Biomaterials Science.

 

Publication profile

Orcid

Education

Assoc. Prof. Dr. Hua Jin earned his Ph.D. in Nanochemistry and Bionanomaterials from Jinan University, Guangzhou, China, from September 2009 to July 2013, graduating in the top 5% of his class. Prior to that, he completed his M.Eng. in Inorganic Chemistry at the same institution from September 2006 to July 2009, also achieving a top 5% ranking. His strong academic background has laid a solid foundation for his innovative research in the fields of chemistry and nanotechnology. 🌟🔬✨

 

Work Experience

Assoc. Prof. Dr. Hua Jin has been an Associate Professor at the College of Medicine, Guangdong Medical University, since September 2018. He brings a wealth of research experience from his postdoctoral fellowships in the United States. From March 2017 to July 2018, he worked at Northwestern University in the Department of Lung Injury and Vascular Disease. Prior to that, from November 2013 to March 2017, he was a postdoctoral fellow in the Department of Pharmacology at the University of Illinois at Chicago. His diverse background enriches his contributions to medical research and education. 🌟🔬

 

Research Achievements

Assoc. Prof. Dr. Hua Jin has made remarkable contributions to research, publishing 50 papers in prestigious SCI journals, showcasing his expertise in his field. His research has garnered significant recognition, with an impressive H-index of 34, reflecting the impactful nature of his work. Dr. Jin also holds two international patents in Australia and three patents in China, highlighting his innovative contributions to science and technology. His achievements demonstrate a commitment to advancing knowledge and pushing the boundaries of research and development. 🌍📚💡

 

Publication Top Notes  

  • Intratracheal Administration of Stem Cell Membrane-Cloaked Naringin-Loaded Biomimetic Nanoparticles Promotes Resolution of Acute Lung Injury (2024) – [Cited by: 2] 🔬
  • Tumor targeting and penetrating biomimetic mesoporous polydopamine nanoparticles facilitate photothermal killing and autophagy blocking for synergistic tumor ablation (2021) – [Cited by: 15] 📈
  • Berberine-Loaded Biomimetic Nanoparticles Attenuate Inflammation of Experimental Allergic Asthma via Enhancing IL-12 Expression (2021) – [Cited by: 10] 🌱
  • Oridonin-Loaded Nanoparticles Inhibit Breast Cancer Progression Through Regulation of ROS-Related Nrf2 Signaling Pathway (2021) – [Cited by: 8] 🥇
  • GE11 Peptide Conjugated Liposomes for EGFR-Targeted and Chemophotothermal Combined Anticancer Therapy (2021) – [Cited by: 5] 💊
  • Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury (2021) – [Cited by: 3] 🐭
  • Peptide-Decorated Supramolecules for Subcellular Targeted Cancer Therapy: Recent Advances (2020) – [Cited by: 20] 📚
  • Macrophage‐Targeted Isoniazid–Selenium Nanoparticles Promote Antimicrobial Immunity and Synergize Bactericidal Destruction of Tuberculosis Bacilli (2020) – [Cited by: 12] 🦠
  • Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis (2020) – [Cited by: 18] 🎯
  • EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy (2017) – [Cited by: 6] 🌼

Divya Jain | Pharmacology Award | Women Researcher Award

Posted on by ScienceFather

Dr. Divya Jain | Pharmacology Award | Women Researcher Award

Dr. Divya Jain, Uttaranchal University, India

Dr. Divya Jain is an accomplished microbiologist, holding a Ph.D. in Microbiology from Banasthali Vidyapith, Rajasthan (2023), an M.Sc. in Microbiology from Graphic Era University, Dehradun (2018), and a B.Sc. in Biotechnology from Banasthali Vidyapith (2016). She currently serves as an Assistant Professor at Uttaranchal University, Dehradun, bringing extensive expertise in microbiology to the Department of Microbiology. Her previous roles include an Associate Research Fellow at the Integrative Centre for Research & Innovation in Biology in Chandigarh. Dr. Jain also completed a notable internship in content and academic writing with The Applied Biology & Chemistry Journal. 📚🔬✨

Publication profile

Orcid

Google Scholar

🎓 Education

Dr. Divya Jain holds a Ph.D. in Microbiology from Banasthali Vidyapith, Rajasthan (2023), an M.Sc. in Microbiology from Graphic Era University, Dehradun (2018), and a B.Sc. in Biotechnology from Banasthali Vidyapith (2016). She completed her high school education in PCB from S.D.R.R Public School, Shamli (2013). 📘🔬

🏢 Work Experience

Currently an Assistant Professor at Uttaranchal University, Dehradun, Dr. Jain also served as an Associate Research Fellow at the Integrative Centre for Research & Innovation in Biology, Chandigarh. 📚🔬

🏅 Certificates and Awards

Dr. Jain has earned several accolades, including the Innovative Article Award and the Excellence in Research Award. She has also completed certificate courses in microbiology, forensic science, and RJ-Ing. 🏆📜

 

Research Focus 🔬🌍

Dr. Divya Jain’s research is primarily focused on microbiology, environmental science, and pharmacology. Her work includes studying microbial pollution, particularly coliform bacteria, and their environmental impact. She has also contributed significantly to sustainable agriculture through research on plant growth-promoting microorganisms and mycorrhiza. Dr. Jain explores the pharmacological applications of natural compounds, such as propolis and medicinal plants, for cancer therapy and liver protection. Her research extends to evaluating potential inhibitors for SARS-CoV-2 and other viral infections, emphasizing bioactive compounds from natural sources. Her multifaceted research underscores her dedication to addressing critical global health and environmental challenges. 🌱🧬🧪

 

Publication Top Notes

  • “Microbial pollution of water with special reference to coliform bacteria and their nexus with environment” 🌊🦠 (110 citations, 2021)
    S Some, R Mondal, D Mitra, D Jain, D Verma, S Das
    Energy Nexus 1, 100008
  • “Role of mycorrhiza and its associated bacteria on plant growth promotion and nutrient management in sustainable agriculture” 🌱🔬 (90 citations, 2020)
    D Mitra, N Uniyal, P Panneerselvam, A Senapati, AN Ganeshamurthy
    International Journal of Life Sciences and Applied Sciences 1 (1), 1-1
  • “Propolis: An update on its chemistry and pharmacological applications” 🍯⚗️ (73 citations, 2022)
    R Hossain, C Quispe, RA Khan, ASM Saikat, P Ray, D Ongalbek, …
    Chinese medicine 17 (1), 100
  • “Tobacco Smoking and Liver Cancer Risk: Potential Avenues for Carcinogenesis” 🚬🔬 (53 citations, 2021)
    D Jain, P Chaudhary, N Varshney, KS Bin Razzak, D Verma, …
    Journal of Oncology 2021 (1), 5905357
  • “Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro/3CLpro: molecular docking and simulation studies of three pertinent medicinal plant natural components” 🧬🌿 (44 citations, 2021)
    D Verma, D Mitra, M Paul, P Chaudhary, A Kamboj, H Thatoi, P Janmeda, …
    Current Research in Pharmacology and Drug Discovery 2, 100038
  • “Biosynthesis of secondary metabolites based on the regulation of microRNAs” 🧬🧪 (33 citations, 2022)
    R Hossain, C Quispe, ASM Saikat, D Jain, A Habib, P Janmeda, MT Islam, …
    BioMed Research International 2022 (1), 9349897
  • “Hepatoprotective activity of medicinal plants: A mini review” 🌿🛡️ (29 citations, 2020)
    D Jain, P Chaudhary, A Kotnala, R Hossain, K Bisht, MN Hossain
    Journal of Medicinal Plants Studies 8 (5), 183-188
  • “Quercetin and/or Ascorbic Acid Modulatory Effect on Phenobarbital-Induced Sleeping Mice Possibly through GABAA and GABAB Receptor Interaction Pathway” 💤🍊 (25 citations, 2021)
    R Hossain, K Al-Khafaji, RA Khan, C Sarkar, MS Islam, D Dey, D Jain, …
    Pharmaceuticals 14 (8), 721
  • “Anticancer effects of acteoside: Mechanistic insights and therapeutic status” 🧬🎗️ (22 citations, 2022)
    RA Khan, R Hossain, P Roy, D Jain, ASM Saikat, APR Shuvo, M Akram, …
    European Journal of Pharmacology 916, 174699
  • “Carcinogenic effects of N-nitroso compounds in environment” 🚫🦠 (22 citations, 2020)
    D Jain, P Chaudhary, N Varshney, P Janmeda
    Environment Conservation Journal 21 (3), 25-41

Sheryar Afzal | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Dr Sheryar Afzal |  Pharmacology |  Best Researcher Award

Assistant Professor at  College of Veterinary Medicine, King Faisal University, Saudi Arabia

Dr. Sheryar Afzal is an accomplished academic and researcher in the field of pharmacology. He currently serves as an Assistant Professor in the Department of Pharmacology at MAHSA University in Bandar Saujana Putra, Selangor, Malaysia.

profile

Academic Background:

  • Ph.D. in Pharmacology (2011-2016) from Universiti Sains Malaysia, Penang, Malaysia.
  • Master of Science (Hons) in Pharmacology (2000-2003) from the University of Agriculture, Faisalabad, Pakistan.
  • Doctor of Veterinary Medicine (D.V.M.) (1995-2000) from the University of Agriculture, Faisalabad, Pakistan.

Professional Experience:

  • Assistant Professor (February 2023 – Present) at King Faisal University, Saudi Arabia.
  • Assistant Professor (May 2017 – Present) at MAHSA University, Selangor, Malaysia.
  • Lecturer (April 2004 – April 2017) at the University of Veterinary & Animal Sciences, Pakistan.
  • Graduate Assistant (July 2012 – August 2014) at Universiti Sains Malaysia, Penang, Malaysia.
  • Post Graduate Fellow (September 2014 – June 2016) at Universiti Sains Malaysia, Penang, Malaysia.

Research Focus: Pharmacology

Dr. Sheryar Afzal’s research in pharmacology primarily focuses on several key areas:

  1. Pharmacology and Neural Control of Hypertension, Diabetes, and Renal Functions: Dr. Afzal investigates the mechanisms underlying hypertension, diabetes, and renal function control. His work likely includes studying how drugs and physiological processes interact to regulate these conditions, aiming to contribute to better treatment strategies.
  2. Herbal-Pharmacological and Toxicological Evaluation of Indigenous Medicinal Plants: He conducts research into the pharmacological properties and potential toxicological effects of indigenous medicinal plants. This research is crucial for understanding the safety and efficacy of traditional remedies and their potential as sources of new therapeutic agents.
  3. Pharmacokinetic Analysis of Natural and Synthetic Drugs: Dr. Afzal also focuses on pharmacokinetic studies, analyzing the absorption, distribution, metabolism, and excretion of both natural compounds and synthetic drugs. This research aids in optimizing drug dosage regimens and understanding drug interactions within biological systems.

Through his research, Dr. Sheryar Afzal aims to advance the field of pharmacology by exploring novel therapeutic avenues, enhancing drug safety profiles, and improving treatment outcomes for various health conditions.

Citation:

  • Total Citations:
    • All-time: 543
    • Since 2019: 351
  • h-index:
    • All-time: 12
    • Since 2019: 10
  • i10-index:
    • All-time: 13
    • Since 2019: 11

Publication Top Notes:

  • Paclitaxel and immune system
    • Authors: A Javeed, M Ashraf, A Riaz, A Ghafoor, S Afzal, MM Mukhtar
    • Journal: European Journal of Pharmaceutical Sciences, 2009
    • Citations: 180
  • The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19
    • Authors: A Attiq, LJ Yao, S Afzal, MA Khan
    • Journal: International Immunopharmacology, 2021
    • Citations: 70
  • Renal denervation restores the baroreflex control of renal sympathetic nerve activity and heart rate in Wistar-Kyoto rats with cisplatin-induced renal failure
    • Authors: SA Khan, MA Sattar, HA Rathore, MH Abdulla, F Ud Din Ahmad, A Ahmad, S Afzal, …
    • Journal: Acta Physiologica, 2014
    • Citations: 38
  • A critical review of pharmacological significance of Hydrogen Sulfide in hypertension
    • Authors: A Ahmad, MA Sattar, HA Rathore, SA Khan, MI Lazhari, S Afzal, F Hashmi, …
    • Journal: Indian Journal of Pharmacology, 2015
    • Citations: 33
  • Antioxidant activity and free radical scavenging capacity of L-arginine and NaHS: A comparative in vitro study
    • Authors: A Ahmad, MZ Sattar, HA Rathore, AI Hussain, SA Khan, T Fatima, S Afzal, …
    • Journal: Acta Pol Pharm, 2015
    • Citations: 33
  • Polarity-Based Solvents Extraction of Opuntia dillenii and Zingiber officinale for In Vitro Antimicrobial Activities
    • Authors: MI Umar, A Javeed, M Ashraf, A Riaz, MM Mukhtar, S Afzal, R Altaf
    • Journal: International Journal of Food Properties, 2013
    • Citations: 23
  • GC-MS and HPLC profiles of phenolic fractions of the leaf of Telfairia occidentalis
    • Authors: OA Eseyin, MA Sattar, HA Rathore, F Aigbe, S Afzal, A Ahmad, M Lazhari, …
    • Journal: Pakistan Journal of Pharmaceutical Sciences, 2018
    • Citations: 22
  • Phytochemical analysis and antioxidant activity of the seed of Telfairia occidentalis Hook (Cucurbitaceae)
    • Authors: OA Eseyin, A Daniel, TS Paul, E Attih, E Emmanuel, J Ekarika, S Afzal, …
    • Journal: Natural Product Research, 2018
    • Citations: 19
  • Interaction between irbesartan, peroxisome proliferator-activated receptor (PPAR-γ), and adiponectin in the regulation of blood pressure and renal function in spontaneously …
    • Authors: S Afzal, MA Sattar, EJ Johns, MH Abdulla, S Akhtar, F Hashmi, …
    • Journal: Journal of Physiology and Biochemistry, 2016
    • Citations: 18